Calisto Medical, Inc. is reporting that it has obtained positive results in a pre-clinical trial of the prototype glucose monitor Glucoband®. The device is based on the company’s proprietary technology called Bio-Electric Impedance Spectroscopy (BEIS). More about the device:
The Glucoband is a compact electronic scanning device that utilizes a bio-electromagnetic resonance phenomenon to non-invasively measure blood glucose levels in the human body, and to continuously monitor the blood glucose level.
A wrist-watch-like Glucoband, with fully integrated LCD screen, electronic circuits, integrated electrodes, battery and adjustable wrist-band, is placed on the person’s wrist. The initial measurement process takes only a few minutes, however, in the monitoring mode, measurements can be continuous and only the frequency of measurements must be determined. The Glucoband targets diabetics who are measuring their own blood glucose, and medical personnel who are using blood glucose measuring and monitoring devices in clinics, hospitals and other point-of-care facilities. The measurements meet FDA requirements for accuracy and correlation…
Bio-Electromagnetic Resonance (BEMR™) technology is based on the detection of a change of electrical impedance in the human body caused by an externally applied glucose-specific electromagnetic wave (‘glucose signature’).
Three known Phenomena are utilized in the Glucoband:
— Each concentration of Glucose solution has its unique electromagnetic molecular self-oscillation signature-wave – ‘glucose signature’.
— Human body is experiencing BEMR when a signature-wave matching any internal molecular self-oscillation wave is applied.
— Due to the BEMR, the body is changing its electrical impedance.